Improving patient selection for immuno‐oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center
Ghassan Al Darazi(Institut Claudius Regaud), Thomas Filleron(Institut universitaire du cancer de Toulouse Oncopole), Jean‐Pierre Delord, Muriel Poublanc(Institut Claudius Regaud), Myriam Estrabaut(Institut Claudius Regaud), Sarah Bétrian(Institut Claudius Regaud), Carlos Gomez‐Roca(Université Fédérale de Toulouse Midi-Pyrénées), Iphigenia Korakis(Institut Claudius Regaud), E. Martin(Institut de Cancérologie de l'Ouest)
Cited by 17
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry
|Journal of Clinical Oncology|2017|357